Clinical Endoscopy

Review

Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events: Min Kyu Kim, Sung Wook Hwang; Clin Endosc 2024;57(6):725-734. Published online August 29, 2024; DOI: https://doi.org/10.5946/ce.2024.003

The use of immune checkpoint inhibitors (ICIs) for the treatment of various malignancies is increasing. Immune-related adverse events can occur after ICI administration, with gastrointestinal adverse events constituting a significant proportion of these events. When ICI-related diarrhea/colitis is suspected, endoscopic evaluation is recommended to differentiate it from other etiologies and assess the severity of colitis. The distribution of intestinal inflammation in ICI-related colitis demonstrates a high frequency of extensive colitis (23–86%). However, isolated right-sided colitis (3–8%) and ileitis (2–16%) are less prevalent. Endoscopic findings vary and predominantly encompass features indicative of inflammatory bowel disease, including aphthae, ulcers, diffuse or patchy erythema, mucosal edema, loss of vascular pattern, and friability. The presence of ulcers and extensive intestinal inflammation are associated with a reduced response to treatment. Microscopic inflammation can be observed even in endoscopically normal mucosa, underscoring the need for biopsies of seemingly normal mucosa. Histological findings present with acute/chronic inflammation and occasionally exhibit characteristics observed in inflammatory bowel disease, microscopic colitis, or ischemic colitis. The first-line therapeutic choice for ICI-related diarrhea/colitis with a common terminology criteria for adverse events grade of 2 or above is corticosteroids, whereas infliximab and vedolizumab are recommended for refractory cases.

Citations

Citations to this article as recorded by

Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis
Diego Casas Deza, Cristina Polo Cuadro, Marta Gascón Ruiz, Manuel Barreiro-de Acosta, Míriam Mañosa, Francisco Rodríguez-Moranta, Yamile Zabana, Elena Céspedes Martínez, Ingrid Ordás, José Miranda Bautista, María José García, Irene García de la Filia Moli
Journal of Clinical Medicine.2026; 15(1): 353. CrossRef
Enteropathogenic Escherichia coli and Bacterial Overgrowth Co-infection Exacerbating Immune Checkpoint Inhibitor-Induced Colitis
Ermias A Kibru, Abdul-Rahaman A Ottun, John G Dusek, Eunice Hama, Bezawit M Fikadu
Cureus.2026;[Epub] CrossRef
Who is at risk for immune checkpoint inhibitor-induced colitis among Korean patients?
Ji Hyun Kim, Sung Chul Park
The Korean Journal of Internal Medicine.2025; 40(1): 3. CrossRef
A Case Report of Metastatic Melanoma in the Transverse Colon
Sophia Bee Ting Tan, Michael Lamparelli
Cureus.2025;[Epub] CrossRef
Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report
Chao Han, Sujuan Xi, Te Shi, Haiyan Yue
Immunotherapy.2025; 17(9): 631. CrossRef
Endoscopic insights into digestive-related adverse effects of immune checkpoint inhibitors: A narrative review
Grigorios Petrousis, Sylwester Szczegielniak, Haider Sabhan, Peter Elbe, Gülden Bilican, Hans Strid, Francesca Bresso, Charlotte Hedin, Stephan L Haas
World Journal of Gastrointestinal Endoscopy.2025;[Epub] CrossRef
Risk factors for steroid-refractory in immune checkpoint inhibitor-induced colitis: a retrospective cohort study
Ke Meng, Jing Chen, Junzhe Chen, Shengjie Sun, Hui Li, Guanzhou Zhou, Fei Pan
Frontiers in Immunology.2025;[Epub] CrossRef
CD8+ cell dominance in immune checkpoint inhibitor-induced colitis and its heterogeneity across endoscopic features
Min Kyu Kim, Hye-Nam Son, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Shinkyo Yoon, Sung Wook Hwang
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef

7,982 View
474 Download
6 Web of Science
8 Crossref

First
Prev
Page of 1
Next
Last

Search